Effects of corneal thickness on the intraocular penetration of travoprost 0.004%.
|Autores:||Martinez-de-la-Casa JM, Rayward O, Saenz-Frances F, Santos-Bueso E, Mendez-Hernandez C, Herrero-Vanrell R, Garcia-Feijoo J, Garcia-Sanchez J.|
|Títuto Revista:||Eye (Lond).|
|Colaboradores:||Instituto de Investigaciones Oftalmológicas Ramón Castroviejo - UCM (RD07-0062-0000)y Grupo de Diseño de Productos Biomateriales Oftálmicos (DEPBO) de la Facultad de Farmacia de la UCM (RD07-0062-2002).|
To determine whether the intraocular penetration of travoprost 0.004% is affected by central corneal thickness.
Sixty-four patients who were scheduled for cataract surgery without any other ophthalmologic pathology of significance were enrolled in this study. At 120 min before surgery, one drop of travoprost 0.004% was instilled in the eye to be operated on. At the start of surgery, a sample of aqueous humour was extracted to subsequently determine its AL-5848 concentration. These concentrations were compared among three groups of patients established according to central corneal thickness measurements obtained by ultrasound pachymetry.
Mean AL-5848 concentrations were 3.27±2.03 ng/ml in Group I (CCT<511 microns), 3.27±2.44 ng/ml in Group II (CCT≥511 and ≤574 microns), and 2.73±2.15 ng/ml in Group III (CCT>574 microns), indicating no significant differences among the groups.
We were unable to demonstrate the greater or lesser penetration of travoprost depending on corneal thickness, which could explain differences in patient responses to this drug.